Medpace (NASDAQ:MEDP) CEO August Troendle Sells 27,174 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 27,174 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the sale, the chief executive officer directly owned 561,195 shares in the company, valued at approximately $347,261,854.05. This trade represents a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Medpace Trading Up 1.3%

NASDAQ MEDP opened at $620.75 on Friday. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The stock has a market capitalization of $17.33 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.73 and a beta of 1.15. The stock has a 50-day moving average of $550.16 and a 200 day moving average of $492.71.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently made changes to their positions in MEDP. Johnson Financial Group Inc. purchased a new position in Medpace during the second quarter worth about $27,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Elyxium Wealth LLC acquired a new position in Medpace during the fourth quarter worth $30,000. Jones Financial Companies Lllp purchased a new stake in Medpace during the second quarter worth $30,000. Finally, Allied Private Wealth LLC acquired a new stake in Medpace in the second quarter valued at $31,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on MEDP shares. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Mizuho upped their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Truist Financial raised their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Finally, Royal Bank Of Canada lifted their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and a consensus price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.